



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/787,421

02/26/2004

Majed M. Hamawy

960296.99187

5432

27114

7590

05/22/2008

QUARLES & BRADY LLP

411 E. WISCONSIN AVENUE, SUITE 2040

MILWAUKEE, WI 53202-4497

EXAMINER

ROONEY, NORA MAUREEN

ART UNIT

PAPER NUMBER

1644

NOTIFICATION DATE

DELIVERY MODE

~~05/22/2008~~

ELECTRONIC

02/11/08

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

pat-dept@quarles.com

Advisory Action Before the Filing of an Appeal Brief	Application No. 10/787,421	Applicant(s) HAMAWY, MAJED M.	
	Examiner Nora M. Rooney	Art Unit 1644	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 28 January 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. ☒ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

- a) ☒ The period for reply expires 3 months from the mailing date of the final rejection.
b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. ☒ The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
(a) ☒ They raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ They raise the issue of new matter (see NOTE below);
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)).

4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. ☐ Applicant's reply has overcome the following rejection(s): _____.
6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7. ☒ For purposes of appeal, the proposed amendment(s): a) ☒ will not be entered, or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed: _____.
Claim(s) objected to: _____.
Claim(s) rejected: _____.
Claim(s) withdrawn from consideration: _____.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
9. ☐ The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. ☐ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: _____.
12. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). _____.
13. ☐ Other: _____.

Maheer M. Haddad

MAHER M. HADDAD
PRIMARY EXAMINER

Continuation of 3. NOTE: The proposed amendments to claim 17 do not overcome the outstanding rejections under 112, first paragraph. Further, the amendments raise new issues with respect to the outstanding rejections. Specifically, whether or not the phosphorylated marker protein is of a particular specified size does not overcome the outstanding rejections because there is no evidence provided in the specification or the art that would suggest that the claimed method would specifically detect the protein or fragment of SEQ ID NO:1.

The Examiner has provided evidence that other kidney proteins, namely I κ B is between 20 and 80 kD. Not only are the majority of all proteins between 20-80 kD, the Examiner has provided evidence to show that one of the most important proteins for cellular function that is present in kidney cells is between 20 and 80 kD. Applicant's assertion that "under certain conditions" I κ B is phosphorylated is a complete distortion because those "certain conditions" occur constantly and are responsible for numerous essential cellular functions. The art shows that the importance of I κ B to cellular function is absolutely undebatable (In particular, see Wardle et al., Jalal et al. and Kerr et al.; PTO-892 mailed on 10/03/2007; whole documents). Applicant's assertion that there is nothing of the record to support that substantial quantities of phosphorylated I κ B would survive homogenation is unpersuasive because the claims do not require homogenation. Applicant's assertion that there is no support for I κ B decreasing once it is created supports the Examiner's assertion that the claimed method does not work. If the claimed method is directed at detecting phosphorylated proteins between 20 and 80 kD in kidney samples and it is known that I κ B is phosphorylated and in that size range, then why is the method not always detecting that protein? Why is there not always a false positive? Applicant's recited method does not detect any specific protein or fragment thereof in a kidney sample or homogenate. Therefore, the method cannot be used to detect kidney transplant rejection.